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There are very few cases of primary pericardial sarcomas reported in the English literature. Pericardial tumors, like other cardiac
tumors, are most likely to be metastatic in nature and are an extension of primary tumors from the surrounding structures.
Sarcomas are the most common primary pericardial tumors. Surgical eradication of the tumor is considered to be the treatment
of choice. Weare presenting a case of a primary pericardial, high-grade pleomorphic undiﬀerentiated sarcoma that was diagnosed
at our institution. We discuss the available diagnostic modalities and also shed light on alternative therapies when patients are not
ideal surgical candidates.
1.Introduction
Cardiac neoplasms are either primary or secondary; in case
of secondary neoplasms the most common site of origin is
the lung [1]. The cardiac involvement can be endocardial,
myocardial, or pericardial, but tumors only involving the
parietal pericardium are not considered to be true cardiac
tumors. Primary cardiac tumors are rare; the incidence is
reported to be around 0.056–0.02% [1]. Malignant tumors
involving the pericardium are even rarer in autopsy series,
the incidence is reported to be around 0.001%. Pericardial
tumors, like other cardiac tumors, are most likely to be
metastatic in nature and are an extension of primary tumors
from the surrounding structures.
Pericardial tumors often cause symptoms related to
malignant pericardialeﬀusion.The presentingsymptoms are
cough, dyspnea, chest pain, and palpitations, which are a
resultofthemasseﬀectofthetumoronthecardiacchambers
[2]. These tumors are of a particular concern due to the
fact that overt signs and symptoms occur rather late in
the course, precluding eﬀective tumor eradication [2]. We
are presenting a case of a primary pericardial, high-grade
pleomorphic undiﬀerentiated sarcoma that was diagnosed at
our institution and provide a brief insight into the detection
and treatment of the disease.
2.Case Presentation
A 67-year-old Caucasian gentleman presented to our insti-
tution with acute right-sided chest pain. He had been
experiencing gradually worsening shortness of breath on
exertion for a few months. Physical examination revealed a
malnourished moderately built male with tachycardia and
muﬄed heart sounds. Chest radiography revealed a widened
mediastinum and an enlarged heart that was suspicious
for a pericardial eﬀusion. A transthoracic echocardiogram
(TTE) conﬁrmed a large anterior pericardial eﬀusion with
respirophasic blunting of the inferior vena cava but no
right ventricular diastolic collapse (Figure 1). A computed
tomography(CT)scanthatcloselyfollowedtheTTErevealed
an anterior mediastinal mass arising from the pericardium,
compounded by the previously documented pericardial
eﬀusion(Figure 2).Pericardial ﬂuid cytologyrevealedmalig-
nant cells. CT guided ﬁne needle aspiration cytology of
the pericardial mass was done. Histopathology showed a
moderately cellular, spindle cell neoplasm with pleomorphic
n u c l e ii nam y x o i db a c k g r o u n d( Figure 3). The pathologists
did ﬁnd pseudolipoblasts, which are found in many tumors
includingpleomorphicliposarcomas(which canbeconfused
with undiﬀerentiated sarcomas [3]). Immunohistochemistry
was positive for vimentin, CD163 and CD 68, other muscle2 Cardiology Research and Practice
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Figure 1:Echocardiographic imageshowinganterior andposterior
pericardial eﬀusion.
speciﬁc markers but melanocytic markers were negative. The
tumor was diagnosed as a primary pericardial high-grade
pleomorphic undiﬀerentiated sarcoma.
Surgery is themost eﬀectivetreatment forsarcoma; how-
ever our patient was not considered to be an ideal surgical
candidate due to the advanced nature of his disease and
poor nutritional state. Oncology was consulted and further
treatment options of radiation and chemotherapy were
discussed with the patient. Doxorubicin was not considered
a feasible option in his case due to its cardiotoxic potential
hence a decision was made to attempt a trial of imatinib
mesylate and further testing of the pericardial mass for c-kit
staining was done. The tumor was found to be c-kit negative
suggesting that chemotherapy with imatinib was unlikely to
be of beneﬁt and the patient was started on a radiotherapy
protocol. Eventually the patient succumbed to the disease in
am a t t e ro fm o n t h s .
3.Pathology
Sarcomas are the most common primary pericardial tumors;
other tumors that involve the pericardium are mesothe-
liomas, lymphomas, and hemangiomas. Among the sarco-
mas, undiﬀerentiated sarcomas (previously called malignant
ﬁbrous histiocytomas) are most frequent. These are thought
to arise from primitive mesenchymal cells and are composed
ofhistiocyticandﬁbroblasticelementsinastoriformpattern.
The use of immunohistochemistry, cytogenetics and molec-
ular diagnostics has made it possible to identify other types
of sarcomas including myxoid, giant cell, inﬂammatory,
and angiomatoid sarcomas [3, 4]. Undiﬀerentiated sarcomas
are further classiﬁed into high-grade pleomorphic sarcoma,
pleomorphic sarcoma with giant cells, and pleomorphic
sarcoma with predominant inﬂammation on the basis of
their histologic appearance [5]. Multiple studies have proved
that undiﬀerentiated sarcoma is but a common pathway
for developing sarcomas and that a tissue of origin should
be actively sought before labeling a soft tissue sarcoma as
Figure 2: CT showing anterior mediastinal mass arising from the
pericardium.
Figure 3: Histopathology showing a moderately cellular, spindle
cell neoplasm with pleomorphic nuclei in a myxoid background.
an undiﬀerentiated sarcoma [5, 6]. Pleomorphic undiﬀer-
entiated sarcomas are commonly seen in elderly males and
involve the thigh, upper arm, and the retroperitoneum [3].
We have presented a high-grade pleomorphic undiﬀerenti-
ated sarcoma arising from the pericardium that is very rarely
documented in English literature.
4.Diagnosis
In case of cardiac sarcomas, a TTE is a good initial diagnostic
test to detect the associated pericardial eﬀusion. With the
use of contrast echocardiography the sensitivity of detecting
malignant tumors increases due to the increased pixel inten-
sity of tumors as compared to the surrounding myocardium
[7].Notall pericardial tumorsare associated withpericardial
eﬀusion and computed tomography (CT) scan is useful in
the detection of such cases. The CT scan ﬁnding of peri-
cardial nodularity is highly suggestive of a pericardial tumor
[8]. Another distinct advantage over TTE is that CT scan canCardiology Research and Practice 3
identify the dominant mass and oﬀer guidance for biopsies
of the mass [8]. Advanced modalities like multidetector CT
scans and cardiac magnetic resonance imaging are gaining
favor as the imaging of choice for diagnoses of pericardial
sarcomas but they are expensive and their availability is
limited [9]. Tissue sampling in the form of surgical biopsies
provides the best odds for detection of the cell of origin.
Since pleomorphic undiﬀerentiated pattern can be found
adjacent to areas of well-diﬀerentiated sarcomas in the same
tumor, the distinction between pleomorphic undifferentiat-
ed sarcomas and other sarcomas can pose a diﬃcult problem
for a pathologist [10]. This makes it imperative that every
eﬀort should be made to obtain as much tissue as possible to
prevent misdiagnoses. Accurate tissue diagnoses have been
shown to aﬀect prognosis since myogenic diﬀerentiation is
considered to be more aggressive than some of the other
pleomorphic sarcomas [6]. A surgical biopsy is fraught with
periprocedural risks depending on the site of the tumor. We
suggest that multiple CT-guided biopsies from diﬀerent ac-
cessible sites should be preferred over open surgical biopsies
[2, 6].
When such a disease process is suspected, a less inva-
sive procedure like pericardial ﬂuid cytology will provide
information regarding the presence of malignancy. It is well
accepted that pericardial ﬂuid cytology is indicated in as-
ymptomatic young adults who have an incidental ﬁnding
of a pericardial eﬀusion. We suggest that pericardial ﬂuid
cytology should also be extended to older individuals who
do not have an obvious underlying cause for an eﬀusion, in
an eﬀort to get a lead time advantage for diagnosing a peri-
cardial malignancy. Positive cytology should be followed by
multiple CT-guided biopsies in an eﬀort to make an accurate
tissue diagnosis, to guide treatment and also assesses the true
prevalence of these tumors [6].
5.Management
Surgery is the mainstay of treatment for soft tissue sarcomas
and eﬀective tumor removal depends on the anatomic lo-
cation of the tumor. Pericardial sarcomas may be amenable
to removal if detected very early on but our case reﬂects
that this may not be possible due to its covert presentation.
The response of soft tissue sarcomas to radiation has been
well documented and currently adjuvant radiation is rec-
ommended along with surgical resection to improve overall
survival [5, 11, 12].
Chemotherapy is currently reserved for metastatic tu-
mors and the agents of choice are doxorubicin and ifos-
famide, with response rates ranging from 55–66% [13, 14].
In case ofpericardial sarcomas, theuse of chemotherapeutics
may extend to the treatment of the primary tumor if surgery
is ineﬀective. The use of doxorubicin in pericardial sarcomas
may be restricted due to its cardiotoxicity which may con-
found the mass eﬀects of the tumor and further worsen
cardiac reserve. The detection of pericardial tumors should
prompt clinicians to enroll these patients into studies that
determine the eﬃcacy of novel chemotherapeutics [15].
The tumor should be evaluated for the presence of speciﬁc
targets (for newer experimental agents) like c-kit, epidermal
growth factor receptor, vascular endothelial growth factor
receptor, and platelet growth factor receptor, among others
[15, 16]. Gemcitabine has shown promise in the treatment
of soft tissue sarcomas that have failed anthracycline-based
chemotherapeutic regimen [17, 18]. Trials with imatinib
mesylate have shown some beneﬁt in gastrointestinal soft
tissue sarcomas, and ongoing multicenter trials for its use
in other soft tissue sarcomas have shown modest results
[19]. Further studies are needed to guide chemotherapeutic
management.
6.Prognosis
Pleomorphic undiﬀerentiated sarcomas in general have a 2-
year survival rate of 60% with a high rate of recurrence and
metastasis. In a series of 200 cases of undiﬀerentiated sarco-
mas, the rate of recurrence after primary tumor eradication
was around 44% [3]. The rate of metastasis was around 42%
and correlated with the depth of the tumor spread, with
deepertumorspossessing greaterpotentialformetastasis [3].
The rates for survival, metastasis, and recurrence speciﬁc for
primary pericardial sarcomas are not available. Given the
close proximity of these tumors to vital structures, it is quite
possible that mass eﬀect of the tumor itself may be lethal,
making metastasis and recurrence less important issues.
7.Discussion
The relative paucity of such cases makes it diﬃcult to design
management protocols speciﬁc to pericardial sarcomas. De-
tection starts by identiﬁcation with contrast enhanced TTE,
pericardial ﬂuid cytology which should be followed by accu-
rate tissue diagnosis with multisite CT-guided biopsies and
cardiothoracic surgery consultation. Currently we believe
that surgical approach should be the primary modality of
treatment. However if patients are not found to be ideal
surgical candidates then chemotherapy and radiation should
be oﬀered requiring a multidisciplinary approach by cardi-
ology and oncology. Enrollment in clinical trials involving
chemotherapeutic agents should always be considered in this
patient population.
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